Results 171 to 180 of about 8,581 (194)

Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial.

JAMA Netw Open
Johnson MW, Naudé GP, Hendricks PS, Garcia-Romeu A.   +3 more
europepmc   +1 more source

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial. [PDF]

BJPsych Open
Beidas Z, Ragnhildstveit A, Blackman A, Anderson T, Fewster E, Syed OA, Sobolenko V, Kanca IK, Jaglinska M, Son T, Farb N, Petranker R.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

Journal of Psychopharmacology, 2022
Natalie Gukasyan, Alan K Davis, Frederick S Barrett   +2 more
exaly  

Dose–response relationships of psilocybin-induced subjective experiences in humans

Journal of Psychopharmacology, 2021
Tim Hirschfeld, Timo Torsten Schmidt
exaly  

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change

Journal of Affective Disorders, 2023
Richard J Zeifman, Candice M Monson, Robin L Carhart-Harris   +2 more
exaly  

Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial

Journal of Psychopharmacology, 2023
Jordan Sloshower, Patrick D Skosnik, Shariful A Syed   +2 more
exaly  

The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation

Journal of Psychopharmacology, 2022
James Rucker, Lindsey Marwood, Catherine Bird   +2 more
exaly  

Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use

Journal of Psychopharmacology, 2023
Natalie Gukasyan, Roland R Griffiths, David B Yaden   +2 more
exaly